|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In the present study, we investigated the transcriptional levels of NAD(P)H:quinone oxidoreductase 1 (NQO1) and heme oxygenase 1 (HO1) genes, the reporter activity mediated by antioxidant response element (ARE), and the protein level of transcription factor nuclear factor E2-related factor 2 (Nrf2), after administration of three major garlic OSCs--diallyl sulfide (DAS), diallyl disulfide (DADS), and diallyl trisulfide (DATS)--in human hepatoma HepG2 cells.
|
15477009 |
2004 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Low dose (7.5 J/m(2)) UVB exposure of mouse hepatoma, mouse keratinocyte, and human skin fibroblast cells led to the nuclear accumulation of Nrf2 and up-regulation of ARE-mediated gene expression.
|
16951152 |
2006 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Importantly, similar aggregates were identified in more than 25% of human hepatocellular carcinomas (HCC), and induction of Nrf2 target genes was recognized in most of these tumors.
|
21482715 |
2011 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We found new recurrent alterations in four genes (ARID1A, RPS6KA3, NFE2L2 and IRF2) not previously described in HCC.
|
22561517 |
2012 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
CTD_human |
We found new recurrent alterations in four genes (ARID1A, RPS6KA3, NFE2L2 and IRF2) not previously described in HCC.
|
22561517 |
2012 |
|
Liver carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The NFE2L2-KEAP1 and MLL pathways are recurrently mutated in multiple cohorts of HCC.
|
23728943 |
2013 |
|
Liver carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
High-throughput short-read sequencing of exomes and whole cancer genomes in multiple human hepatocellular carcinoma (HCC) cohorts confirmed previously identified frequently mutated somatic genes, such as TP53, CTNNB1 and AXIN1, and identified several novel genes with moderate mutation frequencies, including ARID1A, ARID2, MLL, MLL2, MLL3, MLL4, IRF2, ATM, CDKN2A, FGF19, PIK3CA, RPS6KA3, JAK1, KEAP1, NFE2L2, C16orf62, LEPR, RAC2, and IL6ST.
|
24379610 |
2013 |
|
Liver carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
WES of the HCC tissue uncovered somatic driver mutations in the beta-catenin (CTNNB1) and nuclear-factor-erythroid-2-related-factor-2 (NFE2L2) genes.
|
25016225 |
2014 |
|
Liver carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our study demonstrates the importance of CTNNB1 mutations and NFE2L2-KEAP1 pathway activation in HB development and defines loss of genomic stability and TERT promoter mutations as prominent characteristics of aggressive HB with HCC features.
|
25135868 |
2014 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Collectively, the results first suggested that lower expression of miR-340 is involved in the development of CDDP resistance in hepatocellular carcinoma cell line, at least partly due to regulating Nrf2-dependent antioxidant pathway.
|
25556489 |
2014 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here, we demonstrated that AMPK activator AICAR, in contrary to the A769662 allosteric activator, induces Nrf2 activation and concomitantly modulates the basal redox state of the hepatocarcinoma cells.
|
25058527 |
2014 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Hepatocellular carcinomas divert glucose metabolism to the anabolic shunt by activating transcription factor NRF2.
|
24203292 |
2014 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mutations of Keap1 occurred at a much lower frequency in both preneoplastic lesions and HCCs and were mutually exclusive with those of Nrf2.
|
25783764 |
2015 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our study showed that miR-141 plays a key role in 5-FU resistance by down-regulating Keap1 expression, thereby reactivating the Nrf2-dependent antioxidant pathway, which may serve as a potential target for overcoming 5-FU resistance in hepatocellular carcinoma cells.
|
25896253 |
2015 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Nrf2 was up-regulated in HCC, and expression of Nrf2 was correlated with tumor differentiation, metastasis, and tumor size.
|
26194347 |
2015 |
|
Liver carcinoma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
Clinical implication of Keap1 and phosphorylated Nrf2 expression in hepatocellular carcinoma.
|
27650414 |
2016 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
An inhibitor of phosphorylated p62-dependent Nrf2 activation suppresses the proliferation and anticancer agent tolerance of HCC.
|
27345495 |
2016 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
High p62 expression is needed for activation of NRF2 and mTORC1, induction of c-Myc, and protection of HCC-initiating cells from oxidative stress-induced death.
|
27211490 |
2016 |
|
Liver carcinoma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
Here, we aimed to investigate the correlation between NRF2, Kelch-like ECH-associated protein 1 (KEAP1) syntheses and p62 phosphorylation in HCC.
|
27246794 |
2016 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Gankyrin has an antioxidative role through the feedback regulation of Nrf2 in hepatocellular carcinoma.
|
27091842 |
2016 |
|
Liver carcinoma
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, HCC cell treatment significantly decreased the expression levels of Nrf2 and its downstream effectors,
|
27213353 |
2016 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
p62/SQSTM1 is a multifunctional signaling hub and autophagy adaptor with many binding partners, which allow it to activate mTORC1-dependent nutrient sensing, NF-κB-mediated inflammatory responses, and the NRF2-activated antioxidant defense. p62 recognizes polyubiquitin chains via its C-terminal domain and binds to LC3 via its LIR motif, thereby promoting the autophagic degradation of ubiquitinated cargos. p62 accumulates in many human liver diseases, including nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC), where it is a component of Mallory-Denk bodies and intracellular hyaline bodies.
|
27404485 |
2016 |
|
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The results suggested that apigenin sensitizes BEL-7402/ADM cells to doxorubicin through miR-101/Nrf2 pathway, which furtherly supports apigenin as a potential chemo-sensitizer for hepatocellular carcinoma.
|
29137246 |
2017 |
|
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Expression of Nrf2 (n = 100) and 8-OHdG (n = 53) was remarkably increased in HCC tissues compared with the noncancerous hepatic tissues.
|
28281193 |
2017 |